PMID- 34425505
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210920
IS  - 1936-5233 (Print)
IS  - 1936-5233 (Electronic)
IS  - 1936-5233 (Linking)
VI  - 14
IP  - 11
DP  - 2021 Nov
TI  - Effect of aerobic exercise on acquired gefitinib resistance in lung 
      adenocarcinoma.
PG  - 101204
LID - S1936-5233(21)00196-0 [pii]
LID - 10.1016/j.tranon.2021.101204 [doi]
LID - 101204
AB  - Lung adenocarcinoma patients with epidermal growth factor receptor 
      (EGFR)-activating mutations respond well to tyrosine kinase inhibitors but 
      typically develop resistance. Current therapies mainly target differentiated 
      cells, not cancer stem cells (CSCs), but CSCs affect the occurrence, invasion, 
      metastasis and treatment sensitivity of malignant tumours. Recently, aerobic 
      exercise has emerged as adjuvant therapy for cancer. Aerobic exercise can 
      accelerate blood circulation, improve tissue oxygen supply, reduce the stress 
      level of patients, improve the antioxidant capacity of the body, and facilitate 
      the degradation of hypoxia-inducible factor-1 (HIF-1) in tumour tissues, thus 
      weakening its maintenance effect on CSCs. In this study, we successfully 
      established lung adenocarcinoma cell lines with gefitinib resistance. Long-term 
      gefitinib induction could increase the level of oxidative stress in lung 
      adenocarcinoma cells and reduce the antioxidant capacity, resulting in the high 
      expression of HIF-1 and ALDH1 and leading to the enrichment of CSCs, and a 
      decreased response to gefitinib. This may be one of the important reasons for 
      gefitinib-acquired resistance in lung adenocarcinoma. In the case of drug 
      resistance, effective aerobic exercise could reduce ROS, activate SOD, inhibit 
      HIF-1 and ALDH1, and cause a reduction in CSCs to sensitise cells to gefitinib 
      again and ultimately inhibit the malignant proliferation of tumours. Therefore, 
      in the treatment of lung adenocarcinoma, the inhibitory effect of aerobic 
      exercise on oxidative stress can enhance the response of drug-resistant cells to 
      gefitinib and can be used as an effective adjunct measure in the treatment of 
      lung adenocarcinoma.
CI  - Copyright (c) 2021. Published by Elsevier Inc.
FAU - Yang, Hong
AU  - Yang H
AD  - School of PE, Henan University of Science and Technology, Luoyang 471023, China. 
      Electronic address: kdtyyh@163.com.
FAU - Liu, Yiwen
AU  - Liu Y
AD  - Henan Key Laboratory of Microbiome and Esophageal Cancer Prevention and 
      Treatment, Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First 
      Affiliated Hospital (College of Clinical Medicine) of Henan University of Science 
      and Technology, Luoyang 471003, China.
FAU - Kong, Jinyu
AU  - Kong J
AD  - Henan Key Laboratory of Microbiome and Esophageal Cancer Prevention and 
      Treatment, Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First 
      Affiliated Hospital (College of Clinical Medicine) of Henan University of Science 
      and Technology, Luoyang 471003, China.
LA  - eng
PT  - Journal Article
DEP - 20210821
PL  - United States
TA  - Transl Oncol
JT  - Translational oncology
JID - 101472619
PMC - PMC8383010
OTO - NOTNLM
OT  - Acquired drug resistance
OT  - Aerobic exercise
OT  - CSCs
OT  - Gefitinib
OT  - Lung adenocarcinoma
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2021/08/24 06:00
MHDA- 2021/08/24 06:01
PMCR- 2021/08/21
CRDT- 2021/08/23 20:28
PHST- 2021/05/12 00:00 [received]
PHST- 2021/08/03 00:00 [revised]
PHST- 2021/08/14 00:00 [accepted]
PHST- 2021/08/24 06:00 [pubmed]
PHST- 2021/08/24 06:01 [medline]
PHST- 2021/08/23 20:28 [entrez]
PHST- 2021/08/21 00:00 [pmc-release]
AID - S1936-5233(21)00196-0 [pii]
AID - 101204 [pii]
AID - 10.1016/j.tranon.2021.101204 [doi]
PST - ppublish
SO  - Transl Oncol. 2021 Nov;14(11):101204. doi: 10.1016/j.tranon.2021.101204. Epub 
      2021 Aug 21.